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Abstract
In the field of regenerative medicine, generating numerous transplantable
functional cells in the laboratory setting on a large scale is a major challenge.
However, the in vitro maintenance and expansion of terminally differentiated
cells are challenging because of the lack of specific environmental and
intercellular signal stimulations, markedly hindering their therapeutic
application. Remarkably, the generation of stem/progenitor cells or functional
cells with effective proliferative potential is markedly in demand for disease
modeling, cell-based transplantation, and drug discovery. Despite the potent
genetic manipulation of transcription factors, integration-free chemically defined
approaches for the conversion of somatic cell fate have garnered considerable
attention in recent years. This review aims to summarize the progress thus far
and discuss the advantages, limitations, and challenges of the impact of full
chemicals on the stepwise reprogramming of pluripotency, direct lineage
conversion, and direct lineage expansion on somatic cells. Owing to the current
chemical-mediated induction, reprogrammed pluripotent stem cells with
reproducibility difficulties, and direct lineage converted cells with marked
functional deficiency, it is imperative to generate the desired cell types directly by
chemically inducing their potent proliferation ability through a lineage-
committed progenitor state, while upholding the maturation and engraftment
capacity posttransplantation in vivo. Together with the comprehensive
understanding of the mechanism of chemical drives, as well as the elucidation of
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specificity and commonalities, the precise manipulation of the expansion for
diverse functional cell types could broaden the available cell sources and enhance
the cellular function for clinical application in future.
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Direct lineage expansion; Hepatocyte expansion; Cell fate specificity; Transcriptional
memory; In vivo induction
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Core tip: Chemical-mediated reprogramming is a promising strategy for generating
desired cells. However, chemical-mediated pluripotent reprogramming has
reproducibility difficulties, and direct lineage conversion shows significant deficiency in
cell function maturation. On the other hand, direct lineage expansion from target cells
not only bypasses pluripotency-related tumorigenesis but also has superior
posttransplantation advantages in engraftment and functional maturation. Recent
achievements in chemical expansion of human hepatocytes may help solve the cell
source limitation in liver disease treatment.
Citation: Ge JY, Zheng YW, Liu LP, Isoda H, Oda T. Impelling force and current challenges
by chemicals in somatic cell reprogramming and expansion beyond hepatocytes. World J
Stem Cells 2019; 11(9): 650-665
URL: https://www.wjgnet.com/1948-0210/full/v11/i9/650.htm
DOI: https://dx.doi.org/10.4252/wjsc.v11.i9.650
INTRODUCTION
The barriers to cell fate conversion between somatic cells and pluripotent cells had a
breakthrough  with  the  proposition  of  the  induced  pluripotent  stem  cell  (iPSC)
reprogramming strategy in  2006,  when Takahashi  et  al[1,2]  reported  a  significant
discovery that the ectopic expression of four defined transcription factors (TFs; Oct4,
Sox2, Klf4a, and c-Myc) could force the cell fate conversion. Remarkably, iPSCs can be
converted into multiple functional cells under optimal differentiation strategies, not
only contributing to the establishment of patient-specific disease models but also
benefiting drug discovery and development[3-5]. Later, combinations of lineage-specific
TFs were screened and applied to generate various desired cell types, known as direct
lineage conversion, including neurons, cardiomyocytes, hepatocytes, and pancreatic
β-cells[6-9]; this strategy bypasses the transition pluripotent stage, rendering the process
faster and more effective and, meanwhile, evading the risk of pluripotency-related
tumorigenesis, holding great promise for biomedical applications[10,11].
However, to date, TF-based reprogramming approaches face numerous challenges
in efficiency, especially in safety, regarding the use of oncogenes and likely genetic
integration  of  exogenous  factors.  Researchers  have  made  substantial  efforts  to
optimize the reprogramming using nonviral and nonintegrating methods, including
synthetic RNAs[12,13], cell membrane–permeable proteins[14], episomal plasmids[15], and
chemical compounds[16]. Comparatively, chemicals offer several unique advantages
such as structural stability; spatiotemporal flexibility; easy for screening, application,
and delivery; amenability to manufacturing and scale-up; and the possibility of fine-
tuning their effects by altering their concentrations and combinations[17,18]. To date,
several small molecules have been proved to facilitate the iPSCs reprogramming and
lineage  conversion,  either  by  their  substitute  role  for  replacing  certain  TFs,  or
synergetic effect for augmenting the efficiency[19-22].  Additionally, the progressive
attainment of full chemical-induced human pluripotent and lineage-committed cells
merits great promise to resolve the cell source limitation for the therapeutic purpose
(Figure 1), as well as offer an alternative option for human disease modeling and drug
development.
Perhaps,  establishing a  stable  and efficient  chemical  induction strategy could
fundamentally alter the principal concept of the conventional cell reprogramming
strategy. Nevertheless, to date, the specificity of chemical targets and the correlative
gene network dynamics remain unclear[17,23]. Thus, elucidation of the individual or
synergetic  chemical  force  on  the  cell  pathway  signaling  and  epigenetic  pattern
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Figure 1
Figure 1  The schematic of chemical-driven cell fate change and expansion. The transforming growth factor (TGF)-β and GSK3 pathway inhibitors are commonly
required in pluripotency reprogramming, direct lineage conversion, and expansion. Additional epigenetic modulators (histone deacetylase inhibitors and/or
deoxyribonucleic acid/histone methyltransferase inhibitors) are applied for pluripotency reprogramming, as well as direct lineage conversion, while different lineage
commitments require specific signaling modulations. The combination of TGF-β, GSK3, and ROCK pathway inhibitors could induce the direct lineage expansion of
endoderm-committed cells such as hepatocytes. The direct expansion of ectoderm and mesoderm-committed cells remains unclear and could not be listed here.
*Necessary and/or commonly used compounds.
modulation would be vital to endorse the induction of desired cell types proficiently.
Hence,  this  review  aims  to  summarize  the  updated  progress  and  discuss  the
advantages, limitations, and challenges of the impact of full chemicals on stepwise
reprogramming  of  pluripotency,  direct  lineage  conversion,  and  direct  lineage
expansion on somatic cells.
PLURIPOTENT REPROGRAMMING
The first breakthrough for pluripotency reprogramming by full chemical treatment
was attained in 2013[24].  By screening, Hou et al[24]  first successfully identified the
chemical substitutes for Takahashi et al[1,2]’s four TFs, including VPA, CHIR99021,
616452,  tranylcypromine, Forskolin,  and DZNep (VC6TFZ),  which could convert
mouse fibroblasts into a partially reprogrammed state with high Oct4 expression;
embryonic stem cell-like chemically-iPSs (CiPSCs) could be generated after switching
to 2i (CHIR99021 and PD0325901) medium. Additionally, it  was revealed that an
endogenous pluripotency program could be established by chemically manipulating
the  cell  signaling  pathways.  Although  the  routes  and  mechanisms  underlying
pluripotency reprogramming remain unclear to date, two primary hypotheses reveal
how chemicals drive somatic cells stepwise toward pluripotency.
Stepwise bridges
During the attainment of a pluripotent program, unique extraembryonic endoderm
(XEN)–like  state  was  first  discovered linking fibroblasts  to  pluripotency,  which
markedly expressed XEN genes Sall4, Gata4, Gata6, Sox17, and Sox7[25]. Remarkably,
the  knockdown of  XEN genes  during the  reprogramming markedly impairs  the
generation of CiPSCs, whereas their overexpression is adequate to replace essential
chemicals (CHIR99021, 616452, and Forskolin) for the Oct4-positive XEN-like colony
formation, illustrating that the XEN-like state is a vital intermediate state toward
CiPSCs. Of note, despite different cell origins, the similar activation of the XEN-like
program was reported during the early stage of reprogramming from neural stem
cells (NSCs) and small intestinal epithelial cells (IECs)[26], highlighting that the XEN-
like state serves as a vital and exclusive bridge toward pluripotency. Remarkably, the
reprogramming kinetics and frequency of XEN-like state were highly distinct between
NSCs and IECs. Compared with NSCs, IECs exhibited much rapid and efficient XEN-
like  colony  formation,  which  could  be  explained  by  the  fact  that  the  inherent
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expression of Gata4 and Gata6 in IECs facilitated the conversion of XEN-like program
at an early stage.
After 3 years, the same group reported that the 2C (two-cell stage)-like programs
were key bridges linking the XEN-like state to pluripotency, and the expression level
of  the 2C-like program (Zscan4c,  Zscan4f,  Tcstv1,  Tcstv3,  Lmx1a,  and Sp110)  well
correlated  with  the  reprogramming  potential[27].  The  knockdown  of  2C  genes
markedly impaired the reprogramming efficiency of CiPSCs. Additionally, extensive
loss of deoxyribonucleic acid (DNA) methylation was detected in this stage, which
corroborated  the  hallmark  of  global  epigenetic  reprogramming  in  early
embryogenesis, elucidating further the stepwise establishment of “early embryonic-
like programs’’ toward the complete pluripotency network. Notably, when the 2C-like
program was enhanced by the optimized treatment of  VPA (histone deacetylase
inhibitor), the reprogramming efficiency was markedly augmented.
Chromatin accessibility dynamics
BrdU, commonly used in tracing DNA replication,  was occasionally reported to
facilitate OSKM-induced reprogramming and demonstrated further that it  could
replace  Oct4  in  Yamanaka  factors–mediated  reprogramming  and  promote  full
chemical reprogramming[28]. Nevertheless, to date, the precise mechanisms by which
BrdU promotes TFs and chemical-mediated reprogramming remain unclear. Based on
the benefits of BrdU on closing or opening of chromatin loci, the dynamic chemical
reprogramming process was revealed in the view of chromatin accessibility[29].  At
stage 1 of chemical induction, the AP1 families–related chromatin loci in fibroblasts
were closed gradually, whereas chromatin loci enriched with GATAs, FOXs, KLFs,
and SOXs were opened, which highly corroborated the XEN-like intermediate state,
as  reported  previously[25];  however,  it  markedly  differed  from  TF-mediated
reprogramming,  which does  not  need to  bypass  through this  particular  state[30],
illustrating the  unique epigenetic  dynamics  driven by chemicals.  Following the
treatment of 2iL at stage 2, GATAs- and FOXs-related loci turned to close gradually,
along with the opening for OCT/SOX/KLF families. Notably, BrdU is essential to
correctively open and close chromatin loci enriched with the XEN-like and fibroblast
program at stage 1. Remarkably, in this study, the overexpression of master XEN
genes could not replace BrdU for opening specific loci for the Oct4 expression, which
contradicted a previous study[25].
Despite  published protocols,  currently,  the  successful  induction  of  CiPSCs  is
restricted in limited groups, and the core factors and induction efficiency remain
debatable[25,27-29,31],  which  could  be  partially  explained  by  the  nonspecificity  of
chemicals.  Additionally,  the  targeted  signaling  pathway  and/or  epigenetic
modulation could change much because of the tiny bias of chemical concentrations
and  combinations,  making  it  difficult  to  establish  stable  intermediate  states  or
correctly  open  or  close  the  required  chromatin  loci.  Generally,  the  current  low
reproducibility  raises  severe  challenges  for  enhancing the  stepwise  protocol  for
generating CiPSCs.
DIRECT LINEAGE CONVERSION
Recently, the advancements of TF-mediated direct lineage conversion from somatic
cells to other cell types have garnered considerable attention; this strategy bypasses
the acquisition of pluripotent state and serves a promising approach for generating
numerous types of functional cells. The impact of chemicals was first reported to
facilitate the TF-mediated lineage conversion. Supplemented with specific chemicals,
multiple cells  from different germ layers have been successfully generated from
fibroblasts or other somatic cells with minimal utilization of lineage-specific TFs,
including  neuronal  cells[32-35],  cardiac  cells[36,37],  hepatocytes[22,38],  and  pancreatic
cells[39,40]. Additionally, chemical cocktails could markedly augment the TF-mediated
conversion  with  relatively  high  efficiency  and  purity[22,32].  However,  from  the
perspective potential risks of genetic integration, direct lineage conversion by full
chemicals merits much anticipation at present.
Ectoderm
The first full chemical cocktail reported to generate neural progenitor cells (NPCs)
directly from mouse and human somatic cells was a simple and effective VCR (VPA,
CHIR99021,  and RepSox)  combination[41].  The chemical-induced NPCs (CiNPCs)
exhibited similar transcription profiles as brain-derived NPCs and could self-renew
and further differentiate into different neural lineage cells both in vitro and in vivo.
Later,  using alternative chemical cocktails,  NSC-like cells were attained by other
groups[42,43]. Notably, FGF and Shh signaling pathways recompiled the transcriptional
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and epigenetic programs from fibroblast to neural lineage by modulating the binding
and activation of immediate downstream TFs Elk1/Gli2 to master neural genes[43].
Bypassing the NPC state, direct chemical conversion of mature neurons (CiNs)
from mouse and human fibroblasts has been achieved[44-46]. Compared with fibroblasts,
astrocytes  are  extensively  considered  as  a  preferable  starting  cell  source  for
neurogenesis,  as well  as direct neuron conversion[47,48].  Under chemical-mediated
epigenetic silencing of glial genes, as well as the transcriptional activation of crucial
neural transcriptional factors (NEUROD1 and NEUROGENIN2), human astroglial
cells were reportedly converted into functional neurons efficiently, with the ability to
integrate into local circuits in vivo. Additionally, a recent preprint report of in vivo
direct conversion garnered considerable attention. A study reported successfully
converting resident astrocytes to functional neurons in situ in adult mouse brain[49].
Remarkably, such in situ-generated neurons acquired electrophysiological functions
and could functionally interact with resident neurons in the brain.
Mesoderm
Under the  two-step chemical  treatment  based on CRFVPT (CHIR99021,  RepSox,
Forskolin,  VPA, Parnate,  and TTNPB),  for  the first  time,  mouse fibroblasts  were
successfully  converted to  spontaneously beating cardiomyocyte-like  cells  (CMs)
through a Sca-1+  cardiac precursor-like stage[50].  Later, another study reported the
generation of mouse chemical-induced CMs (CiCMs) by replacing the core chemical
RepSox with another TGF-β inhibitor, A83-01[51]. Notably, CiCMs induced by either
approach expressed cardiomyocyte-specific markers and displayed typical cardiac
calcium flux and electrophysiological features, resembling primary cardiomyocytes.
Remarkably, CiCMs could also be induced directly from resident cardiac fibroblasts in
vivo.  Despite  the  relatively  low  efficiency,  the  induced  cardiomyocytes  could
markedly enhance cardiac functions in myocardial infarction mice[52].
In particular, during the conversion of human CiCMs, platelet-derived growth
factor receptor inhibitors reportedly facilitated the cardiac conversion by suppressing
the  fibroblast  program[53].  Additionally,  the  synergistic  effects  of  chemicals  for
epigenetic  modulation  were  determined,  enabling  cells  responsive  to  extrinsic
cardiogenic signals. Furthermore, the chemicals promoted the chromatin accessibility
of core cardiogenesis genes loci,  enabling effective binding of cardiogenic signal
effectors,  such  as  β-catenin  and  Smad1,  and  ultimately  facilitating  the  cell  fate
conversion.
Endoderm
During the chemical induction of mouse CiPSCs, some studies reported a unique
XEN-like intermediate state[25,26,29]; these extraembryonic endoderm-like cells shared
similar global gene expression patterns and in vivo developmental potential to the
embryo-derived XEN cells[25] and displayed high plasticity for directing endoderm
and ectoderm lineage cells. Under favorable induction conditions, both hepatocytes
and neurons could be generated[54]. Remarkably, when cultured in a lineage-favorable
condition,  the  multipotential  intermediate  status  appeared prone to  incline  to  a
specific direction. Combined with the hepatocyte culture medium and activin A,
mouse endoderm progenitor cells (EPCs) were induced with the robust expression of
endoderm  markers  Sox17,  Foxa2,  Gata4/6,  and  Hnf4a,  while  lacking  ectoderm
markers[55].  Additionally,  chemically  induced  EPCs  (CiEPCs)  displayed  marked
foregut/liver differentiation potential regarding the markedly elevated expression of
Krt8, Krt18, and Krt19. Furthermore, under specific differentiation conditions, both
hepatocyte-like cells (HLCs) and pancreatic lineage cells could be generated.
To date, the induction of human EPCs from somatic cells was restricted to the same
germ layer.  Initiated  from gastrointestinal  epithelial  cells,  human CiEPCs  were
reportedly generated under the support of tissue-specific mesenchymal feeders[56],
endowed with bi-potential differentiation capacity toward hepatocytes, pancreatic
endocrine cells, and IECs. Nevertheless, despite growing evidence demonstrating that
chemicals could facilitate the TF-mediated induction of human endoderm lineage cells
from fibroblasts or other distant lineages, such as hepatocytes[22,38]  and pancreatic
cells[39], there was seldom achievement mediated by a full chemical strategy. Perhaps,
gastrointestinal  epithelial  cells  are  more  amenable  for  CiEPCs  induction  than
fibroblasts because of their proximity in lineage distance. Regarding the difference in
transcriptome and pathway profiles between humans and mice, further chemical
cocktail screening is warranted to attain the direct endoderm conversion from other
germ layers.
DIRECT LINEAGE EXPANSION IN HEPATOCYTES
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Although  direct  lineage  conversion  from  fibroblasts  or  other  somatic  cells  has
established predominant  advantages  for  regenerative  medicine[41,43],  the  relative
deficient functional maturation and engraftment in vivo remain a major obstacle[57]. For
decades, human hepatic cell source is in high demand for liver disease treatment
because of the shortage of available liver organs[58,59]. The generation of a large number
of functional and transplantable hepatic cells merits considerable clinical significance
and  has  garnered  substantial  attention.  In  recent  years,  TF-mediated  direct
reprogramming  of  human-induced  hepatocytes  (hiHeps)  has  garnered  more
attention, overwhelming the conventional iPS-derived HLCs, in terms of markedly
reduced risk of tumorigenesis. Despite the progressive enhancements in efficiency
and purity of hiHeps, the extremely low in vivo repopulation capability, as well as
deficient functions regarding metabolism, markedly hampered their transplantation
applications[60,61]. Most recently, the successive achievements in the chemical induction
of primary hepatocytes highlight the acquisition of highly expandable characteristics
(Table 1), which could markedly promote the development of hepatic cell-based liver
disease therapies.
Lineage-committed cells and progenitors
To break the blockage for expansion, a simple and effective combination of three core
chemicals YAC (Y-27632, A83-01, and CHIR99021) was first reported in 2017, enabling
the conversion of  terminally differentiated rat  and mouse hepatocytes  to  highly
expandable  liver  progenitor-like  state,  with  bi-potential  differentiation capacity
toward mature hepatocytes and biliary epithelial cells[62]. Later, using the same core
chemical combination, the induction of progenitor-like state was established further
by another group with in vivo repopulation and maturation capability[63].
However, the induction effect of YAC was only restricted to hepatocytes originated
from rodents, until the discovery of HGF, which was highlighted to be essential for
establishing a human hepatic progenitor-like state through the ERK-1/2 signaling
activation[64]. Remarkably, during the induction of human hepatocytes by modified
cocktail  HAC (HGF,  A83-01,  and CHIR99021),  not  only were hepatic  progenitor
markers  markedly  elevated  but  also  endoderm and pluripotency  markers  were
detected[64],  suggesting  the  potential  acquisition  of  multilineage  differentiation
capacity other than the hepatic fate. Additionally, nicotinamide, commonly used for
hepatocyte  culture[65,66],  inhibited  the  proliferation  and  even  induced  apoptosis
through the inactivation of SIRT1, offering a clue for long-term culture optimization.
Of  note,  under  the  three-dimensional  differentiation  condition,  the  expanded
progenitor-like cells could regain the expression of hepatitis B virus (HBV) receptor
sodium taurocholate cotransporting polypeptide, which could markedly support the
HBV infection or reactivation modeling[67].
Besides the markedly elevated expression of progenitor-associated markers, the
HAC-based induction approach resulted in the suppressed expression of most mature
hepatocyte markers[64,67]. However, when one of the core chemicals, CHIR99021, was
replaced with Wnt3a,  a  unique proliferative state  was established,  which partly
retained mature hepatocyte characteristics while exhibiting progenitor-associated
identity[68]. Besides the GSK3-mediated Wnt pathway activation, special insight was
provided into the crosstalk between Wnt3a and specific  cell  signaling regarding
hepatic progenitor self-renew and proliferation such as the Hippo–YAP pathway[69].
Moreover,  it  implied  that  the  CHIR99021-mediated  pathway  modulation  could
largely erase the initial memory of hepatocyte identity, while the Wnt3a-mediated
modulation partially sustained these signatures. Remarkably, when induced cells
were  transplanted  in  vivo  for  over  4  mo,  the  human  albumin  secretion  and
repopulation  efficiency  could  attain  a  comparable  level  to  primary  human
hepatocytes, suggesting that these induced cells could serve as the most compatible
hepatic cell source that had ever been reported beyond primary hepatocytes.
Organoid expansion
Using  a  highly  similar  chemical  and  cytokine  cocktail,  both  human and  mouse
primary hepatocytes have been established to form organoids (Hep-Orgs) in a 3D
culture system and stably expand for a long term[70]. Hep-Orgs comprise noncycling
mature hepatocytes and cycling hepatocyte progenitor cells, exhibiting comparable
gene  expression  profiles  and  functions  to  primary  hepatocytes.  Remarkably,
progenitor markers were not markedly elevated in Hep-Orgs, which was considerably
different from that in conventional 2D culture[68]. Despite applying a different Wnt
agonist, R-spondin, instead of Wnt3a, the major discrepancy could be contributed by
the  special  circumstance  in  the  organoid  culture  system,  which  seemingly
recapitulated the regeneration microenvironment of the adult liver in vivo. In Hep-
Orgs,  cell  cycle  and  ribosome synthesis–related  gene  expression  was  markedly
enhanced, resembling the response of hepatocytes to acute liver damage such as
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Table 1  Expandable hepatic cells induced from primary hepatocytes to date
Hepatocyte
source(s) Chemicals Growth factor(s)
Medium and
supplements
Expansion potential
Yr
Passage count Doubling time
Mouse and Rat A83-01, CHIR99021,
Y-27632
EGF DMEM/F12,
HEPES, L-proline,
ITS, dexamethasone,
nicotinamide,
ascorbic acid-2
phosphate, BSA,
antibiotic/
antimycotic
Rat: >10; Mouse: >20 Rat: 14.7 ± 1.1 h 2017[62]
Mouse A83-01, CHIR99021,
Y-27632
EGF, HGF DMEM/F12, N2 or
ITS, S1P, LPA
>30 15-20 h 2017[63]
Human (resected
patient liver tissue,
non-lesion)
A83-01, CHIR99021 EGF, HGF DMEM/F-12 (high
glucose), FBS,
nicotinamide,
dexamethasone, ITS,
penicillin/
streptomycin
>10 37.9-39.8 h 2018[64]
Human (resected
patient liver tissue,
non-lesion)
A83-01, CHIR99021,
Y-27632
EGF, HGF Advanced
DMEM/F-12, N2,
B27, sodium
pyruvate, ascorbic
acid, S1P, LPA
>10 24.7 ± 1.4 h 2018[67]
Human (normal,
cryopreserved)
A83-01, Y-27632 EGF, FGF10, HGF,
Wnt3a
Advanced
DMEM/F-12, FBS,
N2, B27 (minus
vitamin A), N-
acetylcysteine,
nicotinamide,
[Leu15]-gastrin I,
penicillin/
streptomycin,
4 (normoxia); 8
(hypoxia)
2018[68]
Human (normal,
freshly isolated and
cryopreserved)
A83-01, CHIR99021,
Y-27632
EGF, FGF7, FGF10,
HGF, TGFa
Advanced
DMEM/F-12,
HEPES, B27 (minus
vitamin A), R-
spodin1 conditioned
medium, N-
acetylcysteine,
nicotinamide,
gastrin, GlutaMAX,
penicillin/
streptomycin,
Fetal hepatocytes:
>16
5-7 d 2018[70]
partial hepatectomy.
Limitations
Notably, human hepatocyte–induced proliferative cell sources displayed large scale
expandable potential, as well as superior compatibility and functional maturation, for
transplantation  compared  with  iPSCs-derived  HLCs  or  hiHeps,  exhibiting  a
remarkably  higher  repopulation  rate  and  human albumin  secretion[61,71].  As  the
maturation  direction  of  human hepatocyte-induced  proliferative  cell  sources  is
lineage-committed, they did not necessarily require an extra differentiation process,
severing as ready-to-use transplantable sources, and might merit broader prospects
for breaking through the obstacle for liver disease treatment. Nevertheless, currently,
the expansion efficiency of  human hepatocytes is  remarkably lower than that  of
rodent hepatocytes. Compared with rodent hepatocytes, human hepatocytes required
approximately a 10 h longer period for cell doubling, whereas the maximum passage
counts  for  stable  expansion declined approximately 10 times[63,67].  Regarding the
proliferation kinetics, rodent hepatocytes essentially required three to five passages
for establishing an accelerated proliferative state, while human hepatocytes exhibited
a gradual loss of proliferation potential after three to four passages, implying that the
building  of  a  proliferative  intermediate  state  for  human  hepatocytes  might  be
relatively insufficient or unstable. Although a hypoxic expansion condition possibly
inhibited the senescence and prolonged proliferation[68],  an understanding of the
different transcriptome and pathway network profiles between humans and mice is
required to reveal specific signaling for human hepatocyte expansion.
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Telomere shortening during prolonged expansion is another limiting factor[70]. The
unlimited self-renewal and genomic stability of pluripotent stem cells were facilitated
by sufficiently long telomeres[72].  During pluripotent reprogramming, which was
either TF- or chemical-mediated, short telomeres of somatic cells were significantly
elongated  in  a  process  mediated  by  telomerase  activity  upregulation  or  by
recombination-based  ALT  mechanisms[31,73].  Moreover,  reprogramming  triggers
telomere  elongation  regardless  of  donor  age  status[74,75].  Thus,  telomere  erosion,
characterized  in  aged  and  senescent  cells,  can  be  efficiently  rejuvenated  after
pluripotent reprogramming. However, direct lineage conversion and expansion from
somatic cells bypass the pluripotent intermediate status, thereby preserving age-
associated features. Compared with the iPSC-derived counterpart, extensive DNA
damage, loss of heterochromatin and nuclear organization, and increased SA-β-Gal
activity were observed in lineage-converted functional cells[76]. Therefore, even though
the conversion is successfully completed, the converted cells seem to inherit aging
signatures from parental cells, including short telomeres, and be prone to senescence
after passages. During chemical-mediated expansion of primary human hepatocytes,
the inherently short telomeres and insufficient telomerase activation may play a key
role in eliciting senescence of induced proliferative cells after limited passages[68],
which remains a major obstacle for large-scale expansion in vitro.  In contrast,  we
found that when human iPSC-derived HLCs are chemically induced for expansion,
they exhibit a superior expansion advantage compared with primary hepatocytes.
Induced cells  can stably expand for  extended passages while  sustaining hepatic
differentiation potency (unpublished data). The relatively high telomerase activity
inherited from iPSCs potentially restores or elongates telomeres, facilitating long-term
expansion. The ability to use chemicals to activate telomerase and elongate telomeres
in  human terminally  differentiated  cells  such  as  hepatocytes  would  be  of  great
importance for an extended expansion capability.
Moreover, the advantage of the organoid culture system has been proved to be
supportive  for  the  long-term  expansion  with  enhanced  functional  maturation;
however, the current expansion efficiency was much lower than the 2D system, and
the culture condition optimization, such as the extracellular matrix, warrants further
investigation.
Despite the achievements in hepatocytes, direct expansion of other lineage cells,
such as neurons and cardiomyocytes, has been seldom reported. Undoubtedly, the
direct conversion from fibroblasts has already proved a feasible option for generating
these functional cells. It is expected that when the direct lineage expansion is applied,
the in vivo repopulation and functional maturation could be enhanced further.
CHALLENGES
The chemical-mediated direct lineage conversion and expansion, bypassing potential
risks using transgenic methods, as well as pluripotency-related tumorigenesis, offer
promising options for  therapeutic  purpose.  However,  several  challenges remain
regarding the unrevealed mechanism of chemical effects.
Cell fate specificity
To date, several dozens of chemicals have been identified in various combinations for
cell  induction[11,16,18,77].  Although the  precise  mechanism underlying  a  particular
conversion between different cell fates remains unclear, chemical inducers could be
classified into two major groups—epigenetic modulators and signaling regulators.
Epigenetic  modulators,  typically  HDAC  inhibitors  and  DNA/histone
methyltransferase inhibitors, such as VPA and BIX01294, are commonly used for the
induction of CiPSCs, CiNSCs, and CiCMs[27,41,53].  Conversely, signaling regulators
specify the characteristics of the designated cell identity. Reportedly, ISX9 and AS8351
were specific for the CiNs induction[44,78]. Additionally, SC1 was specific for the CiCMs
induction[51,53]. The 2i combination (CHIR99021 and PD0325901) was always required
for the late stage of the CiPSCs induction[24,25]. However, RepSox, A83-01, CHIR99021,
and Forskolin were extensively used as essential factors for inducing various cell
types, including CiPSCs, CiNPCs, CiNs, CiCMs, and CiEPCs[24,43,53,55,78]. The nonspecific
feature of a significant portion of the chemicals could be attributed to the fact that
same signaling pathways are often shared by the multilineage development such as
the Wnt and TGF-β pathways[79]; it may not only extend the induction application for
a broad range of cell types but also possibly lead to undesired cell fates. Using the
same chemical cocktail for the CiPSCs induction, the generation of an unexpected
cardiac fate was uncovered[50]. The possible explanation was that the chemicals might
induce a nonspecific multipotential intermediate state, which was highly plastic and
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unstable;  or  a  heterogeneous  mixture  of  multiple  progenitor  cell  types.  Under
favorable  conditions,  the  induction direction  could  incline  further  to  cardiac  or
pluripotent fate.
To exclude the unanticipated induction fate, it would be challenging to elucidate
further  the individual  and synergistic  effect  of  chemical  cocktails  regarding cell
signaling and epigenetic regulation, as well as the specificity and commonality for
distinct lineages (Table 2), and then develop stepwise reliable chemical cocktails that
could precisely direct the desired cell types.
Cell identity memory
Each  cell  type  has  its  unique  transcriptome,  which  defines  its  cell  identity.
Reprogrammed cells more or less inherit the cell identity memory of their ancestor.
An analysis  of  molecular  traces  during the induction of  iPSC-HLCs and hiHeps
identified original fibroblast identity efficiently but not completely erased in both cell
types[61]. Additionally, iPSC-HLCs exhibited the expression of endoderm progenitor
(FOXA2 and GATA6) and hepatoblast (AFP and EPCAM) markers, suggesting that the
memory of molecular traces during the differentiation path was also sustained in
iPSC-HLCs; however, the hiHeps induction bypasses these cell identities transition,
exhibiting no expression of these markers. Overall, the sustained memory during
reprogramming and differentiation process could elucidate the fact that both c and
hiHeps exhibited distinct characteristics from primary hepatocytes in gene expression
and related functions[80-82].
Additionally, chemical-mediated reprogramming was also challenged by the initial
cell  identity  modulation.  The  investigation  of  the  direct  induction  of  neurons
identified a bromodomain inhibitor, IBET151, as a core compound needed to erase the
initial fibroblast transcriptional network program for cell identity rewriting[78]; the
mechanism could be concerned with the blocking effect that IBET151 disrupted the
accessibility of bromodomain proteins to acetylated histones related to fibroblast
programs, resulting in transcriptional silencing[83]. Additionally, the bromodomain
and extra-terminal domain inhibitors remarkably enhanced iPSC and NPC induction
via switching off a large set of initial somatic transcriptional programs[84]. Besides,
platelet-derived growth factor receptor (PDGFR) inhibitors, SU16F and JNJ10198409,
reportedly accelerated the downregulation of fibroblast genes during the conversion
of human cardiomyocytes, markedly enhancing the efficiency[53].  Perhaps, further
investigation of chemicals with the erase effect on specific cell types would booster the
efficiency of the cell fate conversion.
Conversely, the initial somatic transcriptional memory could also facilitate the
transplantation. In a study, when direct lineage expansion was applied in primary
hepatocytes, their partly sustained hepatocyte transcriptional memory could facilitate
quick engraftment and functional maturation after transplantation in vivo[68]. Of note,
based on our study,  when cells  were chemically  induced form iPSC-HLCs,  they
exhibited relatively low in vivo  repopulation capability,  which corroborated that
before induction (unpublished data). The possible explanation was that the induced
cells  inherited  portions  of  transcriptional  memory of  iPSC-HLCs,  including  the
deficiency in repopulation capability. This discrepancy not only highlights the hurdles
for  transplantation  of  iPSC-derived  functional  cells  but  also  emphasizes  the
elucidation of the cell memory dynamics during induction.
In vivo induction
Conventionally, long-term in vitro expansion is critical to obtain sufficient functional
cells for transplantation, whereas the potential risk of functional alteration and genetic
mutations  from  the  in  vitro  microenvironment  raises  serious  problems [57,85].
Theoretically,  in vivo  reprogramming could produce functional cells followed by
inducing resident  functional  cells  with bi-potency or  proliferation capability,  or
directly  convert  the  neighboring  cell  types  proximal  in  lineage  distance  and,
meanwhile, take advantage of the in situ niche to regenerate the damaged tissue or
organ efficiently, which remains a major obstacle for in vitro circumstances.
In recent years, substantial TF-mediated in vivo reprogramming has demonstrated
some exciting achievements, including neuroblasts or neurons induced from glial
cells[86,87], cardiomyocytes induced from cardiac fibroblasts[88-90], hepatocytes induced
from myofibroblasts[91,92], and pancreatic β-like cells induced from exocrine cells[9,93].
Despite great promise for diseases treatment as demonstrated by previous studies, the
TF-mediated strategy also poses risks of genome integration, tumorigenesis, as well as
manufacturing and delivery problems. Comparatively, chemical-mediated strategy
minimized the risk of genetic alteration and is easier for scalable manufacturing,
stocking, and delivery[23], eventually preferable for in vivo therapeutic applications.
Recently,  for  the  first  time,  in  vivo  chemical  reprogramming  was  reported  to
successfully convert the resident astrocytes into functional neurons in the adult mouse
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Table 2  The specificity and commonality of chemicals in direct lineage conversion
Compounds Function
Target germ layer and cell types
Ref.Ectoderm: Neural
stem/ progenitor cell,
neuron
Mesoderm:
Cardiomyocyte
Endoderm/
extraembryonic
endoderm: Endoderm
progenitor cell, XENs
A83-01 TGF-βRI (ALK4/5/7)
inhibitor
+ +
[42,43,51,53]
AM580 RAR agonist +
[25,54]
AS8351 KDM5B inhibitor +
[53]
Bay K 8644 Ca2+ channel activator +
[51]
BIX01294 Histone
methyltransferase
inhibitor
+ +
[42,53]
CHIR99021 GSK3 inhibitor + + +
[25,41-46,50,51,53-55,78]
DMH1 BMP inhibitor +
[46]
EPZ004777 DOT1L inhibitor +
[25,54]
Forskolin cAMP activator + + +
[25,44-46,50,51,54,55,78]
GO6983 PKC inhibitor +
[44]
Hh-Ag1.5 Smo agonist +
[43]
I-BET151 BET bromodomain
inhibitor
+
[78]
ISX9 Neurogenic agent +
[78]
JNJ10198409 PDGF-RTK inhibitor +
[53]
LDN193189 BMP type I receptor
(ALK2/3) inhibitor
+
[43,45]
OAC2 Oct4 activator +
[53]
Parnate
(Tranylcypromine)
LSD1/MAO inhibitor + + +
[25,43,50,54]
PD0325901 MEK inhibitor +
[42,45]
RepSox (616452) TGF-βRI (ALK5)
inhibitor
+ + +
[25,41,44,46,50,54,55]
RG108 DNA methyltransferase
inhibitor
+
[42,43]
SB431542 TGF-βRI (ALK4/7)
inhibitor
+
[45,78]
SC1 ERK1/RasGAP inhibitor +
[51,53]
SMER28 Autophagy modulator +
[43]
SP600125 JNK inhibitor +
[44,46]
SU16F PDGFRβ inhibitor +
[53]
TTNPB RAR agonist + +
[50,55]
VPA Histone deacetylase
inhibitor
+ + +
[25,41,42,44,46,50,54]
Y27632 ROCK inhibitor + + +
[44,46,53-55]
XENs: Extraembryonic endoderm-like cells.
brain, resembling endogenous neurons in both neuron-specific marker expression and
electrophysiological properties[49]. Meanwhile, cardiomyocytes were induced from
adult cardiac fibroblasts by direct full chemical administration in vivo, and although
the  reprogramming efficiency  is  relatively  low,  the  chemical  cocktail  treatment
markedly decreased the scar formation and enhanced cardiac functions in myocardial
infarction mice[52]; these encouraging achievements not only provide a general strategy
for in vivo  reprogramming but also open a novel path to regenerate the diseased
organs in situ.
However, the off-target or unspecific-target effects of chemicals pose challenges for
the in vivo induction, as the chemical treatment could target undesired cell types in
situ or nearby, potentially declining the intrinsic homeostasis of local cell populations.
Moreover, exogenous chemicals could also break the homeostasis of local niche and
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cause unintended tissue damage. Thus, it will be essential to evaluate the side effects
in vivo in the long term, and the chemical combinations and concentration should be
optimized to adapt physiological homeostasis synergistically. Finally, despite the high
permeability  advantage  of  chemicals  in  tissue,  the  arrival  to  unwanted location
should  be  avoided.  Advances  in  the  delivery  system  are  warranted  to  deliver
chemicals to designated locations for an expected period precisely. Overall, enhanced
targeting and shielding capabilities  will  be  indispensable  for  attaining effective
reprogramming in vivo.
PERSPECTIVES
Generating substantial functional cells with tissue/organ regeneration capability is a
major  challenge  for  regenerative  medicine.  Despite  the  rapid  progress  of  the
conventional strategy regarding the differentiation from pluripotent stem cells[94,95], the
direct  lineage  conversion,  bypassing  the  pluripotent  stage,  has  highlighted  a
promising alternative strategy in recent years[57]. Additionally, chemical-mediated
strategy,  targeting  the  modulation  of  epigenetic  status  and signaling  pathways
without interfering the genome integration, exhibited the unique advantage over
transgenic and other approaches for cell reprogramming, especially regarding the
expansion potential[23,77]. Remarkably, chemically induced cells, including XEN-like
state and lineage-specific stem/progenitors (CiNSCs, CiNPCs, and CiEPCs), exhibited
highly expandable characteristics, which could markedly satisfy the predominant
requirement for clinical use. Additionally, recently reported direct lineage expansion
holds great promise for cell transplantation applications. As these induced cells not
only exhibited the robust proliferation capability but also partly sustained the initial
cell identity memory, it facilitated direct and rapid revert to mature state after in vitro
differentiation or been transplanted in vivo. However, it remains a major obstacle for
direct lineage conversion from fibroblasts or other somatic cells, which exhibited a
significant deficiency in functional maturation. Although the achievement to date in
direct lineage expansion of human functional cells remains highly limited, the success
in human hepatocytes would undoubtedly offer a general idea for extending this
strategy to other desired cell types. Moreover, the limited expansion capability of
induced  human  hepatocytes  also  evokes  the  importance  of  exploring  chemical
candidates to activate telomerase and rejuvenate telomeres, which may potentially
extend expansion of induced cells in vitro (Table 3).
Holding  an  excellent  promise  for  direct  lineage  conversion  and  expansion,
spatiotemporal flexibility and nonintegrative characteristics of  chemical  strategy
could  also  be  favorable  for  the  in  vivo  induction  approach,  offering  superior
advantages for therapeutic potential[94]. As safety and efficiency might be the rate-
limiting step for in vivo reprogramming[96], assistant technology, such as nano-delivery
system, might be required to deliver chemicals  to specifically targeted sites  in a
controlled manner.
Along with the advances of chemical screening, discrete combinations of pathway-
specific chemicals have progressively been identified to reprogram somatic cells into
many lineages. Nevertheless, improved knowledge of the pathway networks, together
with the epigenetic pattern that drives the cell fate conversion and proliferation, is
warranted to intelligently enhance the induction efficiency and specificity in vitro and
in vivo.
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Table 3  Advantages and disadvantages of different strategies for functional cell induction
Strategy Inductionefficiency
Reproducibi
-lity/stability
Target
specificity
Cellular
function
In vivo
engraftment Safety Scaling up Cost Ref.
TF-mediated
pluripotent
reprogramm
ing followed
by
differentia-
tion
Moderate Highly
reproducible/
stable
High Immature Low Genomic
integration;
tumorigenesis
risk
Expandable
before
differentia-
tion
Very high
[11,97-99]
TF-mediated
direct
lineage
conversion
Fast and
efficient
Reproducible
/stable
High Deficient Low Genomic
integration
Expandable
in progenitors
High
[100-103]
Chemical-
mediated
pluripotent
reprogramm
ing followed
by
differentia-
tion
Controversial Poorly
reproducible/
unstable
Low Not clear Not clear Integration-
free
Not clear Low
[24,25,29,31]
Chemical-
mediated
direct
lineage
conversion
Low Reproducible
/ unstable
Low Deficient Low Integration-
free
Expandable
in progenitors
Very low
[18,77,104,105]
Chemical-
mediated
direct
lineage
expansion
Fast and
efficient
Reproducible
/ unstable
Low Close to
primary
High Integration
free
Expandable
in rodents/
Limited in
humans
Very low
[62,64,67,68]
TF: Transcriptional factor; XENs: Extraembryonic endoderm-like cells.
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